Press release
Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference
—New Analyses from the Phase 3 ASPEN Study Examining Efficacy and Safety of Brensocatib Across a Variety of Prespecified Subgroups— —Data from ASPEN Post-hoc
About this update from Insmed Incorporated
[{"type":"text","content":"—New Analyses from the Phase 3 ASPEN Study Examining Efficacy and Safety of Brensocatib Across a Variety of Prespecified Subgroups—\n—Data from ASPEN Post-hoc Analysis Evaluating Changes in Lung Function in Bronchiectasis Patients Who Did or Did Not Experience Pulmonary Exacerbations in the Trial—\n—Data on Health Status Improvements Over Time Following Culture Conversion in Patients with Mycobacterium Avium Complex (MAC) Lung Disease—\nBRIDGEWATER, N.J., March 25, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will present 11 abstracts from across its respiratory portfolio at the American Thoracic Society (ATS) 2025 International Conference, taking place May 18-21, 2025, in San Francisco. Presentations include several prespecified subgroup analyses from the Phase 3 ASPEN study evaluating the efficacy and safety of brensocatib, new health economics and outcomes research in MAC lung disease, and clinical data from the Phase 2a study of treprostinil palmitil inhalation powder (TPIP) in pulmonary hypertension associated with interstitial lung disease (PH-ILD).\n\"Our strong presence at this year's ATS congress underscores our steadfast commitment to advancing groundbreaking research and driving innovation, with the ultimate goal of improving outcomes for patients with serious diseases worldwide,\" said Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed. \"With no treatments specifically approved for bronchiectasis, we are especially eager to present several new subgroup analyses from ASPEN, the largest Phase 3 clinical trial in bronchiectasis to date, which will highlight how brensocatib performed across diverse patient types in the study.\"\nPresentations:\nThematic Poster Session A54, Sunday, May 18, 11:30 AM–1:15 PM PT:Treatment Patterns and Outcomes Among Patients with Non-Cystic Fibrosis BronchiectasisHospitalizations and Risk of Readmissions in Patients with Non-Cystic Fibrosis BronchiectasisMini Symposium Session B20, Monday, May 19, 10:03 AM–10:39 AM PT:Healthcare Resource Utilization Associated with Treatment for Refractory Mycobacterium Avium Complex Lung Disease: Comparison of Amikacin Liposome Inhalation Suspension (A...